Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 4/20 | 0.48 |
| ▸ | CASP7 | P55210 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497991 | 0.96 | CYP1A2 (0.46) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5504036 | 0.91 | CYP1A2 (0.48) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5495981 | 0.85 | OPRM1 (0.49) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5500147 | 0.85 | HTR6 (0.42) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| Hydrochloric Acid SCHEMBL5500127 | 0.84 | OPRM1 (0.55) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5496840 | 0.81 | OPRM1 (0.48) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5498080 | 0.79 | MAPT (0.49) | CYP1A2CYP3A4USP2ALDH1A1CASP1 | |
| SCHEMBL5506316 | 0.77 | OPRM1 (0.51) | IDO1TDO2IDO2OPRM1OPRK1 | |
| SCHEMBL5999528 | 0.76 | ALDH1A1 (0.46) | CYP1A2CYP3A4USP2ALDH1A1HSD17B10 | |
| SCHEMBL5496623 | 0.74 | OPRM1 (0.53) | USP2ALDH1A1TSHRHTR6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789050-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006016278-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY, LLC | 2006-02-09 | — | — | US | claimed |
| EP-1789050-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006016278-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY, LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | CYP1A2 281/4885CYP3A4 1077/4885USP2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.